Product Description
KW-6500: (Apomorphine hydrochloride hydrate) under development for the treatment of hypanakinesia from Parkinson's disease-related motor complications. KW-6500 was also granted an orphan drug designation in March of 2011. (Sourced from: https://www.kyowakirin.com/media_center/news_releases/2011/e20110726_01.html)
Mechanisms of Action: D2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kyowa Hakko Kirin
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-070504 |
JapicCTI-070504 | P2 |
Completed |
Parkinson's Disease |
2008-10-01 |
|||
NCT00610103 |
NCT00610103 | P2 |
Completed |
Parkinson's Disease |
2008-10-01 |
2019-07-12 |
Treatments |
|
JapicCTI-090850 |
JapicCTI-090850 | P3 |
Completed |
Parkinson's Disease |
None |
|||
JapicCTI-101014 |
JapicCTI-101014 | P3 |
Completed |
Parkinson's Disease |
2011-09-01 |
|||
NCT01063621 |
6500-005 | P3 |
Completed |
Parkinson's Disease |
2011-08-01 |
2019-07-12 |
Treatments |
|
NCT00955318 |
NCT00955318 | P3 |
Completed |
Parkinson's Disease |
2010-12-01 |
2019-07-12 |
Treatments |
|
NCT01058291 |
6500-004 | P3 |
Completed |
Parkinson's Disease |
2010-10-01 |
2019-07-12 |
Treatments |
|
JapicCTI-101013 |
JapicCTI-101013 | P3 |
Completed |
Parkinson's Disease |
2010-09-01 |
Recent News Events
Date |
Type |
Title |
|---|